Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.
Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.
Shanghai Henlius used the 2026 J.P. Morgan Healthcare Conference to announce an exclusive global license for a potentially best-in-class anti-IL-1RAP monoclonal antibody that expands the company beyond oncology into high-unmet-need autoimmune and inflammatory diseases.
Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical companies entered 2026 by raising list prices on hundreds of brand-name medicines, underscoring the limited impact of recent policy efforts on the broader U.S. drug pricing landscape.
The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.
The president recently announced the healthcare initiative as an effort to bring healthcare price transparency to American patients.
Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the build-out of its commercial infrastructure and access strategy, and preparations for a potential FDA decision in early 2027.
Hayley Burgess SVP, Inovalon, talks about how specialty pharmacists are evolving from dispensers into precision-care partners, using integrated data, automation, and AI to personalize therapy decisions.
In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined strategy focused on sustained growth over the next decade, AbbVie highlighting continued pipeline advancements as it prepares for future revenue transitions, and Novavax detailing its shift toward a partnership-driven operating model.
Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on monetizing its Matrix-M platform through diversified royalties and disciplined cost control.
Graham Goodrich, CCO, Apnimed, positions AD109 as a long-awaited, patient-acceptable therapy for untreated sleep apnea that delivers meaningful improvements in oxygenation, daily functioning, and peace of mind.
Hayley Burgess SVP, Inovalon, touches on integrated care mentioning to the industry's priority of shared real-time data across payers, providers, and pharmacies, can lead to it becoming reality.
In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focused company is emerging following years of transformation, Merck detailing its strategy to de-risk long-term funding and pipeline investment, and Eli Lilly reinforcing its confidence in sustaining GLP-1-driven growth.
Genmab used the 44th Annual J.P. Morgan Healthcare Conference to reposition itself as it enters 2026 with a reshaped business model.
Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.
Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully established biotech, marked by team expansion, facility growth, and validation of its sustained-delivery platform.
Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using technology to unify data, streamline workflows, and proactively monitor high-risk patients across care transitions.
Bayer’s strategic portfolio refresh, late-stage pipeline progress, and operational efficiency positions the company for long-term growth across cardiovascular, oncology, and women’s health.
Regeneron CEO Len Schleifer highlighted the company’s science-driven platform approach, strong 2025 commercial performance, and a robust pipeline across multiple therapeutic areas poised for regulatory filings, clinical milestones, and new product launches.
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, and continued cost discipline.
Michael O'Rourke, CEO of Re-Vana Therapeutics, frames Re-Vana's early-stage, platform-led model as credible to public-market investors, pointing to clinical validation of sustained biologic delivery and strong collaboration interest.
Hayley Burgess SVP, Inovalon, talks about rising data fragmentation, access barriers, and adherence risks pushing specialty pharmacies to adopt integrated, end-to-end platforms that consolidate clinical, operational, and patient data.
In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.
Pfizer entered the 44th Annual J.P. Morgan Healthcare Conference emphasizing its post-Covid reset, improved cost discipline, and a catalyst-heavy pipeline aimed at navigating the patent cycle and reaccelerating growth into 2026 and beyond.
Johnson & Johnson reinforces its long-term domestic investment strategy with a new $2 billion biologics facility in Wilson, North Carolina, further elevating the state’s role as a global life sciences hub.
Michael O' Rourke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its sustained-delivery hydrogel technologies to support both internally developed assets and external pharma collaborations.
Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while navigating fragmented data systems, access hurdles, and prior authorization demands that strain pharmacists’ abilities.
Johnson & Johnson reached a voluntary agreement with the U.S. government to enhance patient access, lower drug costs, and expand domestic manufacturing.
Financing announcements across the pharma sector reflect the industry’s continued interest in advancing clinical-stage programs across genetic medicine, immunology, and chronic diseases.
In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans and AI can jointly create value in pharma, and Eli Lilly enters a billion-dollar agreement to acquire Ventyx Biosciences.
